The Hedge Book logo The Hedge Book Read smarter. Invest better.

AI Stock Monitor

DIVISLAB.NS - Divi's Laboratories

Company-specific Hedge Book research coverage for Divi's Laboratories, classified in Pharmaceutical Ingredients and Contract Manufacturing within Healthcare. Verified developments are interpreted through its sector, industry, and company-specific monitoring framework.

Public company · India · Healthcare · Pharmaceutical Ingredients and Contract Manufacturing

NSE · Healthcare · Research updated · Market data updated Research and source refreshes run four times daily. The timestamps above identify the latest successful research and market-data updates.
Hedge Score 70 /100
BullishBullish
Confidence61%
Community Bullish0%
Followers2
Current Price₹8,300.001D +0.3%

Price History

DIVISLAB.NS chart

8,300.006,921.885,543.754,165.622,787.50 Aug 2021Jun 2022Apr 2023Feb 2024Dec 2024Oct 2025Aug 2026 2021-08-08 4,948.702024-02-11 3,729.202026-08-10 8,300.00

AI-Assisted Chart Analysis

Divi's Laboratories technical analysis

Calculated from verified chart history for the selected tenor; no news or fundamental assumptions are used.

Technical only
Trend

Constructive uptrend: the latest level is above the 50-period average and the 50-period average is above the 200-period average.

Momentum

RSI is 86, a extended reading. Above 70 can signal extension; below 30 can signal exhaustion.

Support scenario

The first technical watch zone is 6,116.50. A break below 5,689.50 invalidates the near-term support setup.

Resistance scenario

The first resistance/watch zone is 8,300.00. A confirmed break above 8,300.00 supports continuation.

Risk

Annualized realized volatility is +61.9%. Maximum lookback drawdown is -48.1%, from a high-water mark of 5,372.15 to 2,787.50.

Potential levels are conditional chart scenarios, not personalized advice or instructions to buy or sell.

How To Read This Stock Brief
Hedge Score

Higher means the current research setup is stronger across signal, confidence, catalysts, risk balance, and market context. Lower means the setup is weaker or less supported.

Confidence

Higher confidence means the evidence is more consistent and relevant. It does not mean the stock has that percentage chance of going up.

Signal

Bullish, Bearish, or Neutral is the current AI research stance. It is designed to help you ask better questions, not to replace your decision process.

Community Bullish

This shows how signed-in users are voting. It is useful sentiment context, not proof that the crowd is right.

Read the full Hedge Score and confidence methodology

What Changed Today

  • Divi's Laboratories has formally released its earnings call transcript, providing the official management narrative regarding recent operational performance and strategic outlook. Concurrently, updated mutual fund shareholding data for June 2026 has been published, reflecting institutional positioning changes that occurred prior to the current reporting period. Technical analysis metrics, including RSI, MACD, and moving averages, have been updated to reflect the most recent market close, though these indicators remain distinct from the company's fundamental operational data.

Why It Matters

  • The earnings call transcript serves as the primary source for evaluating management's guidance on revenue growth, operating margins, and potential shifts in contract manufacturing demand.
  • While institutional flow data offers insight into market sentiment and liquidity, it does not directly influence the company's balance sheet or cash flow generation.
  • Investors must prioritize the qualitative and quantitative disclosures within the transcript to adjust valuation models, as technical indicators and historical ownership data are lagging metrics that do not capture real-time operational changes.

AI Opinion

  • Read: The current evidence-grounded AI read is bullish.
  • Evidence: The publication of the earnings call transcript is the most material development, as it provides the necessary context to assess management's tone and forward-looking strategy.
  • Uncertainty: Technical analysis and mutual fund flow data provide secondary signals regarding market sentiment but lack predictive power for the company's core pharmaceutical manufacturing business.
  • Watch: The current evidence lacks specific, actionable details from the transcript, necessitating a granular review to identify shifts in contract manufacturing demand or regulatory status.

Key Risks

  • Reliance on technical indicators or historical institutional flows can lead to mispricing if the market ignores fundamental shifts in the company's contract manufacturing pipeline. A divergence between technical momentum and actual operational performance could increase volatility, particularly if institutional investors adjust positions based on the latest earnings commentary.
  • The earnings call transcript may reveal unforeseen challenges in API manufacturing or regulatory compliance that could compress operating margins. If management commentary indicates increased scrutiny or delays in product approvals, this would weaken the earnings outlook and likely trigger downward revisions in analyst estimates.

Upcoming Catalysts

  • Future filings will reveal whether the June 2026 mutual fund activity represents a trend of accumulation or distribution. A sustained increase in institutional ownership following the earnings call would act as a positive signal for market confidence, whereas divestment could signal skepticism regarding the company's near-term growth trajectory.
  • Specific commentary in the earnings transcript regarding future revenue growth and capital expenditure plans will serve as the primary catalyst for valuation adjustments. Confirmation of sustained demand in contract manufacturing would strengthen the thesis, while vague guidance on margins could lead to increased uncertainty.

Upcoming Events

7:00 AM CSTDaily monitor scheduled

The automated scan is configured to refresh the stock brief each morning.

Market hoursPrice and news watch

The monitor checks price action, company news, filings, sector read-throughs, and major macro drivers.

Next catalystEvent watch

Upcoming earnings, product, policy, and industry events are tracked for thesis-changing updates.

Hedge Score Drivers

  • Verified evidence is currently bullish across the covered research lanes.
  • Evidence currently covers earnings and financial trends, sector and industry context, catalysts, risks, price and sentiment context.
  • Confidence is constrained by missing or incomplete evidence for balance-sheet strength, company operating KPIs, valuation.

Last Updated

Sources and verification

Each generated research claim remains linked to its supporting update. Primary evidence comes from filings, company materials, or regulators; secondary evidence provides additional context.

  • The Hedge Book: Upcoming CatalystSecondary sourceReportedNews · Published 2026-08-07Open verification sourceSupports: Upcoming Catalysts
  • The Hedge Book: Upcoming CatalystSecondary sourceReportedNews · Published 2026-08-07Open verification sourceSupports: Upcoming Catalysts
  • The Hedge Book: Upcoming CatalystSecondary sourceReportedNews · Published 2026-08-06Open verification sourceSupports: Upcoming Catalysts
  • The Hedge Book: Key RiskSecondary sourceReportedNews · Published 2026-08-07Open verification sourceSupports: Key Risks
  • The Hedge Book: Key RiskSecondary sourceReportedNews · Published 2026-08-07Open verification sourceSupports: Key Risks
  • The Hedge Book: Key RiskSecondary sourceReportedNews · Published 2026-08-06Open verification sourceSupports: Key Risks
  • The Hedge Book: AI OpinionSecondary sourceReportedNews · Published 2026-08-07Open verification sourceSupports: Company-Specific Research Updates
  • The Hedge Book: AI OpinionSecondary sourceReportedNews · Published 2026-08-07Open verification sourceSupports: Company-Specific Research Updates
  • The Hedge Book: AI OpinionSecondary sourceReportedNews · Published 2026-08-06Open verification sourceSupports: Company-Specific Research Updates
  • The Hedge Book: Why It MattersSecondary sourceReportedNews · Published 2026-08-07Open verification sourceSupports: Why It Matters, AI Opinion
  • The Hedge Book: Why It MattersSecondary sourceReportedNews · Published 2026-08-07Open verification sourceSupports: Why It Matters, AI Opinion
  • The Hedge Book: Why It MattersSecondary sourceReportedNews · Published 2026-08-06Open verification sourceSupports: Why It Matters, AI Opinion
  • The Hedge Book: What Changed TodaySecondary sourceReportedNews · Published 2026-08-07Open verification sourceSupports: What Changed Today, Why It Matters, AI Opinion
  • The Hedge Book: What Changed TodaySecondary sourceReportedNews · Published 2026-08-07Open verification sourceSupports: What Changed Today, Why It Matters, AI Opinion
  • The Hedge Book: What Changed TodaySecondary sourceReportedNews · Published 2026-08-06Open verification sourceSupports: What Changed Today, Why It Matters, AI Opinion
  • Divi's Laboratories RSI, Moving Averages, Technical Analysis MACD, MFI, Stochastic and Candlesticks of end of the day - Trendlyne.comSecondary sourceReportedNews · Published 2026-08-07Open verification sourceSupports: What Changed Today, Why It Matters, AI Opinion
  • Divis Laboratories Ltd - 532488 - Announcement under Regulation 30 (LODR)-Earnings Call Transcript - trendlyne.comSecondary sourceReportedNews · Published 2026-08-06Open verification sourceSupports: What Changed Today, Why It Matters, AI Opinion
  • Mutual Fund Jun 2026 share holdings and fund action in Divi's Laboratories - Trendlyne.comSecondary sourceReportedNews · Published 2026-07-31Open verification sourceSupports: What Changed Today, Why It Matters, AI Opinion
  • Divi's Laboratories RSI, Moving Averages, Technical Analysis MACD, MFI, Stochastic and Candlesticks of end of the day - Trendlyne.comSecondary sourceReportedTrendlyne.com · Published 2026-07-17Open verification sourceSupports: What Changed Today, Why It Matters, AI Opinion
  • Accumulate Divis Laboratories; target of Rs 8600: Prabhudas Lilladher - Moneycontrol.comSecondary sourceReportedMoneycontrol.com · Published 2026-08-03Open verification sourceSupports: What Changed Today, Why It Matters, AI Opinion
  • DIVISLAB Share Price Today: Divi's Laboratories NSE - TickertapeSecondary sourceReportedNews · Published 2026-07-30Open verification sourceSupports: What Changed Today, Why It Matters, AI Opinion
  • Divis Laboratories Ltd Share Price Today - Zee BusinessSecondary sourceReportedNews · Published 2026-08-01Open verification sourceSupports: What Changed Today, Why It Matters, AI Opinion
  • Divi 's Laboratories Limited - BSESecondary sourceOfficialNews · Published 2026-08-01Open verification sourceSupports: What Changed Today, Why It Matters, AI Opinion
  • Divis Laboratories Ltd Share Price Today - Zee BusinessSecondary sourceReportedZee Business · Published 2026-08-02Open verification sourceSupports: What Changed Today, Why It Matters, AI Opinion
  • Divis Laboratories Ltd - 532488 - Board Meeting Outcome for Outcome Of Board Meeting Held On August 01, 2026. - trendlyne.comSecondary sourceReportedNews · Published 2026-08-01Open verification sourceSupports: What Changed Today, Why It Matters, AI Opinion
  • Divi’s Laboratories Q1 profit surges 66% to ₹902 crore, revenue rises 28% - CNBC TV18Secondary sourceReportedCNBC TV18 · Published 2026-08-01Open verification sourceSupports: What Changed Today, Why It Matters, AI Opinion
  • Divi's Laboratories consolidated net profit rises 65.50% in the June 2026 quarter - Business StandardSecondary sourceReportedBusiness Standard · Published 2026-08-01Open verification sourceSupports: What Changed Today, Why It Matters, AI Opinion
  • Divis Laboratories Ltd Share Price Today - zeebiz.comSecondary sourceReportedNews · Published 2026-08-02Open verification sourceSupports: What Changed Today, Why It Matters, AI Opinion
  • Divi's Laboratories - DIVISLAB - stock price prediction, stock forecast, target price, analyst ratings from 30 analysts - Trendlyne.comSecondary sourceReportedNews · Published 2026-07-31Open verification sourceSupports: What Changed Today, Why It Matters, AI Opinion
  • Divi’s Laboratories Q1 profit surges 66% to ₹902 crore, revenue rises 28% - cnbctv18.comSecondary sourceReportedNews · Published 2026-08-01Open verification sourceSupports: What Changed Today, Why It Matters, AI Opinion
Market-data attributionYahoo Finance delayed market data · provider detailsMarket prices are supporting signals only and do not establish the research conclusion.

Community View

Sign in with Google to vote once per stock.

Bullish
Bearish
Neutral

Total votes: 0

Disclaimer

The Hedge Book provides AI-assisted educational market research. It is not a registered investment adviser, broker, dealer, or financial planner. Content may contain errors and should be independently verified. Do not treat this page as personalized advice to buy, sell, or hold any security.